

## Invitation to presentation of Nanexa's year-end report and Q4-report

**Nanexa AB (publ) will tomorrow, the 16th of February, 2023, publish its year-end report for the fiscal year 2022 and interim report for the fourth quarter of 2022, and invites to a comment of the report.**

The live commentary with CEO David Westberg will take place on February 16 at 2:00 p.m. via Infront Direct Studios and viewers will have the opportunity to ask questions via chat.

[The report commentary will be available here](#)

The comment of the report will also be published on Nanexa's website afterwards. The presentation will be held in Swedish.

**For additional information, please contact:**

---

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: [david.westberg@nanexa.se](mailto:david.westberg@nanexa.se)

[www.nanexa.com](http://www.nanexa.com)

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

### **About Nanexa AB (publ)**

---

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

### **Attachments**

---

[Invitation to presentation of Nanexa's year-end report and Q4-report](#)